AIM ImmunoTech announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, CEO of AIM ImmunoTech, gave an overview of Locally Advanced Pancreatic Adenocarcinoma and the unmet need.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech appoints Lapp as a consulting Medical Officer
- AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment
- AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
- AIM ImmunoTech announces interim report data from Ampligen study
